A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

NCT05403749 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL: dose 1 IBI302
DRUG: Aflibercept
BIOLOGICAL: dose 2 IBI302

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.